Physician profile
Jade E Simon
NPI 1023470465
$2,401.35
in general payments reported to CMS, 2019-2025
38 companies · $2,334 in 2025
The $2,334 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.48 · 2023: $31.46 · 2025: $2,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.89 |
| Education | $289.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $223.18 | 2025 | Erleada, Balversa, Akeega |
| Exelixis INC. | $186.39 | 2025 | Cabometyx |
| Astrazeneca Pharmaceuticals Lp | $163.99 | 2025 | Enhertu, Imfinzi |
| Gilead Sciences, INC. | $144.79 | 2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $144.05 | 2025 | Iclusig, Ninlaro |
| Merck Sharp & Dohme LLC | $113.93 | 2025 | Keytruda, Welireg |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Genzyme Corporation | $90.30 | 2025 | |
| Pfizer INC. | $88.30 | 2025 | |
| Incyte Corporation | $80.97 | 2025 | Jakafi, Monjuvi, Zynyz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.31 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.22 | 2025 | |
| Novartis Pharmaceuticals Corporation | $67.71 | 2025 | |
| Springworks Therapeutics, INC. | $66.44 | 2025 | Ogsiveo |
| Array Biopharma INC | $66.18 | 2025 | Mektovi, Tukysa, Braftovi |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $60.84 | 2025 | Ojjaara, Zejula, Jemperli |
| Legend Biotech USA INC. | $50.73 | 2025 | Carvykti |
| Daiichi Sankyo INC. | $50.60 | 2025 | Injectafer |
| Beone Medicines USA, INC. | $48.92 | 2025 | Brukinsa, Tevimbra |
| Abbvie INC. | $40.64 | 2025 | |
| Karyopharm Therapeutics INC. | $35.77 | 2025 | Xpovio |
| Janssen Pharmaceuticals, INC | $35.48 | 2021 | |
| Taiho Oncology, INC. | $34.37 | 2025 | |
| Eisai INC. | $33.54 | 2025 | |
| Adaptive Biotechnologies Corporation | $31.53 | 2025 | Clonoseq |
| Boston Scientific Corporation | $31.46 | 2023 | Watchman Flx |
| Servier Pharmaceuticals LLC | $28.27 | 2025 | |
| Geron Corporation | $27.32 | 2025 | Rytelo |
| Lilly USA, LLC | $26.74 | 2025 | Verzenio, Jaypirca |
| Caris Mpi, INC. | $24.75 | 2025 | Mi Cancer Seek |
| Emd Serono, INC. | $22.55 | 2025 | |
| Genmab U.S., INC. | $21.76 | 2025 | Epkinly |
| Beigene USA, INC. | $21.53 | 2025 | Tevimbra |
| Sobi, INC | $20.57 | 2025 | |
| Syndax Pharmaceuticals, INC. | $20.43 | 2025 | |
| Astellas Pharma US INC | $19.25 | 2025 | Vyloy |
| Stemline Therapeutics INC. | $18.11 | 2025 | Orserdu |
| Pharmaessentia USA Corporation | $16.44 | 2025 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jade Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.